Novo Energies - der kommende Tenbagger!? - 500 Beiträge pro Seite

[Gluecksjaeger]

SOURCE: Novo Energies Corporation

May 19, 2011 08:00 ET

Novo Energies Corp. Enters Into a Memorandum of Understanding to Acquire Biotech Firm Immunovative Clinical Research Inc.

NEW YORK, NY--(Marketwire - May 19, 2011) - Novo Energies Corp. (OTCBB: NVNC) has today announced that it has entered into a Memorandum of Understanding ("MOU") to acquire Immunovative Clinical Research Inc. ("ICRI"), a wholly-owned subsidiary of world-class, Israel-based biotechnology firm Immunovative Therapies, Ltd. ("Immunovative").

After successfully completing a Phase I//II clinical trial, ICRI is currently advancing its lead product, AlloStim™, to Phase II/III clinical trials. Two unmet medical need indications have been targeted for initial development -- 3rd line metastatic colorectal cancer and 3rd line metastatic breast cancer. Successful clinical development in either indication could lead to fast-track market approval and revenue potential in excess of $1 billion for each indication.

Under terms of the agreement, ICRI has the world-wide exclusive license for the marketing rights to all intellectual property currently and in the future owned by Immunovative in exchange for monthly research payments. ICRI also has the exclusive right to manage an Expanded Access Program ("EAP") which allows patients access to Immunovative's experimental products through an agreement with Immunotherapy & Cancer Research Center (Thailand), Ltd., ("iCARE") affiliated with the National Cancer Institute of Thailand. The EAP is expected to generate revenues sufficient to support ICRI operations, including research payment obligations, at or near break-even until the next financing event. In the next 24 months, the results of one or two of the randomized Phase II clinical trials are expected. Successful results will allow the newly merged company to have several financing options available, including licensing, partnership with pharmaceutical companies and institutional investments with private and public equity sources.

About Immunovative's Treatments:

Immunovative develops treatments designed to harness the power of the immune system to seek out and destroy cancer whereever it resides in the body and to remember the cancer so that if the cancer returns, an immune mediated attack can be reinstated to prevent disease recurrence. While this goal has been elucive for immunotherapy companies in the past, Immunovative has developed a breakthrough by reverse engineering an immune response proven to kill human tumors.

The most powerful anti-tumor immune effect ever discovered for human cancer is the immune effect that occurs after a bone marrow/stem cell transplant with cells from a matched tissue donor ("Allogeneic Transplant"). This immune effect is called the graft vs. tumor ("GVT") effect. The GVT effect is capable of killing cancers that are refractory to standard treatments and can also cure certain refractory cancers. However, the clinical application of this powerful GVT effect is limited by the severe and often lethal side-effect of the procedure called graft vs. host disease ("GVHD").

Immunovative has bioengineered a patented cell product called AlloStim™ which elicits the same GVT effect mechanism in patients without GVHD toxicity and without the need for a matched tissue donor.

In a 42 patient, FDA-approved, Phase I/II clinical trial conducted in 2009-2010, AlloStim™ was shown to be the first immunotherapy drug to demonstrate systemic, immune-mediated tumor killing in heavily pre-treated metastatic cancer patients without significant toxicity, validating the novel concept. In these patients with less than 60 days of life expectancy, approximately 20% experienced long-term remission of disease for over 1 year.

Immunovative has also purchased the exclusive rights to a patented technology called Chaperone Enriched Cell Lysate ("CRCL") invented by Dr. Emmanual Katsanis and colleagues at the University of Arizona. CRCL is an individualized anti-cancer vaccine where specialized proteins called heat shock proteins are derived from a sample of a patient's own tumor. The heat shock proteins chaperone tumor antigens to train the immune system to identify the tumor. When CRCL is mixed with AlloStim™, the immune system can be programmed to attack the tumors. The combination of CRCL and AlloStim™ is called AlloVax™. This product is currently under clinical investigation at the National Cancer Institute of Thailand.

Commenting on the MOU, Immunovative Founder and CEO Dr. Michael Har-Noy stated, "I am very excited to enter into the MOU between our wholly-owned subsidiary ICRI and Novo Energies. The new capital available will be used to advance the lead AlloStim™ product into Phase II randomized trials designed to show an over-all survival advantage of the drugs in late stage metastatic colorectal cancer and breast cancer. Our Expanded Access Program has potential to enable the Company to operate without the need for additional capital until the results of these trials are known. This makes the company unique among biotech companies and may limit the amount of future dilution."

Novo Energies CEO Mr. Antonio Treminio commented, "After a period a due diligence, it became clear that the acquisition of ICRI represents a world class opportunity for the shareholders of NOVO Energies. The immunotherapy treatments developed by Immunovative have the potential to prolong lives of desperately ill cancer patients who would otherwise have no hope for survival. The products are unique in that they have shown activity against a wide variety of cancers and can be economically mass produced and distributed. The combined company has a solid foundation on which to build one of the leading companies in the emerging field of cellular immunotherapies. Immunovative is assembling an experienced management team and the company has strong intellectual property positions. These factors should facilitate the newly merged company's growth into a successful enterprise that will provide significant social and financial returns."

About Immunovative Clinical Research ("ICRI")
ICRI is a Nevada Corporation established in February 2009 as a wholly-owned subsidiary of Immunovative Therapies, Ltd. ICRI has the world-wide, exclusive license for the marketing rights to all intellectual property currently and in the future owned by Immunovative. In exchange, ICRI is obligated to support the ongoing research and development activities of Immunovative. Immunovative is eligible for matching funds for approved Research and Development projects from the Israel Office of the Chief Scientist. ICRI is responsible for managing and conducting clinical trials and obtaining regulatory approvals for marketing of products based upon Immunovative intellectual property and managing an Expanded Access program.

About Immunovative Therapies, Ltd. ("Immunovative")
Immunovative is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit corporate website at: www.immunovative.co.il

DISCLAIMER

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on Novo's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Novo has little or no control. Such forward-looking statements are made only as of the date of this release, and Novo assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in Novo's Form 10-K for its fiscal year ended March 31, 2010, and other documents filed from time to time by Novo with the Securities and Exchange Commission.

Contact Information

For more information, please contact:

Mr. Antonio Treminio
Chairman & Chief Executive Officer
Novo Energies Corporation
New York: [phone]
Montreal: [phone]
Email: [e-mail]

Dr. Michael Har-Noy
Founder & Chief Executive Officer
Immunovative Therapies, Ltd.
Israel Tel: [phone]
US Tel: [phone]
Email: [e-mail]

Quelle: http://www.marketwire.com/press-release/novo-energies-corp-e…

[Gluecksjaeger]

Das Portfolio von Immunovative sieht recht vielversprechend aus, haben einiges in der Pipeline.

http://www.immunovative.co.il/

[Gluecksjaeger]

SOURCE: Novo Energies Corporation

October 03, 2011 12:15 ET

Novo Energies Corp. Announces Shareholder Update


NEW YORK, NY--(Marketwire - Oct 3, 2011) - Novo Energies Corp. (OTCBB: NVNC) has today announced a shareholder update whereby the Company voluntarily retracts the press release that it issued on May 19th, 2011 titled "Novo Energies Corp. Enters into a Memorandum of Understanding to Acquire Biotech Firm Immunovative Clinical Research Inc." Earlier this year on May 17th, 2011 the Company entered into a Memorandum of Understanding ("MOU") with Immunovative Clinical Research Inc. ("ICRI"), a Nevada Corporation and wholly-owned subsidiary of Immunovative Therapies, Ltd., an Israeli Corporation ("Immunovative"), pursuant to which the Company and ICRI shall pursue a merger resulting in the Company owning ICRI.

Despite the decision to voluntarily retract the press release, the MOU described therein is still in effect. Novo Energies and Immunovative are now discussing how, and if, to proceed with the MOU and are considering proceeding with an exclusive world-wide license arrangement of all current and future intellectual properties that have been granted or pending in the United States and/or Internationally.

On September 29, 2011, Immunovative provided Novo Energies with a copy of a letter, dated September 26th, 2011 that ICRI received from the U.S. Department of Health & Human Services, Food & Drug Administration (the "FDA"). In that letter, the FDA considers terminating the Investigational New Drug Application ("IND") related to AlloStim™ due to alleged deficiencies in the IND and/or in the conduct of the investigations under the IND. ICRI has been given the opportunity by FDA (within the next 30 days) to provide a written explanation or correction or may request a conference with the FDA to provide the requested explanation. After such response or correction the FDA may decide to accept Immunovative's response as a sufficient remedy to the outstanding issues or may take action to pursue terminating the IND, or may result in Immunovative voluntarily withdrawing the IND.

Dr. Michael Har-Noy, Immunovative's CEO, stated: "We are currently working closely with our regulatory consultants in order to respond completely and fully to the FDA and attempt to address all their concerns. Over the past year, we have made considerable changes and improvements in the manufacturing and formulation processes of our living cell product and these changes have not yet been submitted to FDA review. Should we be able to resolve these problems with the FDA, we plan to submit regulatory documents seeking FDA clearance for a Phase II randomized study."

Novo Energies Corp. has also set out the reasons for the retraction in a current report on Form 8-K filed today with the U.S. and Securities and Exchange Commission (the "SEC"). A copy of that current report may be found on the SEC's EDGAR filing system on the SEC's website (www.sec.gov).

DISCLAIMER

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on Novo's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Novo has little or no control. Such forward-looking statements are made only as of the date of this release, and Novo assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in Novo's Form 10-K for its fiscal year ended March 31, 2010, and other documents filed from time to time by Novo with the Securities and Exchange Commission.

For more information, please contact:

Mr. Antonio Treminio
Chairman & Chief Executive Officer
Novo Energies Corporation
New York: [phone]
Montreal: [phone]
Email: Email Contact


Quelle: http://www.marketwire.com/press-release/novo-energies-corp-a…

[VanGillen]

Also ich reagiere gar nicht mehr auf das in englisch geschriebene.Und schon mal gar nicht wenn da keine Daten der Aktie stehen.
Na dann lass es Dir mal gut gehen.

[Gluecksjaeger]

Dec. 15, 2011, 11:36 a.m. EST

Novo Energies Corporation Licenses Immunovative Therapies, Ltd.'s New Generation of Immunotherapy

NEW YORK, NY, Dec 15, 2011 (MARKETWIRE via COMTEX) -- Novo Energies Corporation ("Novo") /quotes/zigman/557259 NVNC +10.00% today announced that it has signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("Immunovative"), an Israeli biopharmaceutical company, developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer.

Immunovative has 10 U.S. patents granted, 15 U.S. patents pending and 26 corresponding applications pending internationally and has in-licensed a patent from the University of Arizona related to an individualized cancer vaccine using Chaperone Enriched Cell Lysate (CRCL). Immunovative has two experimental immunotherapy products for the treatment of cancer in clinical development: AlloStim(TM) and AlloVax(TM) ("Product Candidates") covered by these patents and patent applications. Under the terms of the License Agreement, Novo has been granted an exclusive, worldwide license to commercialize any products covered under Immunovative's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. The license also includes the right to charge fees for sublicensing to third parties by indication and territory.

Immunotherapy is a new modality for cancer treatment that may hold great promise for becoming a new class of therapy for cancer treatment that features minimal toxicity and works together with or replaces current treatment methods. Many past immunotherapy/cancer vaccines have had disappointing clinical results. Immunovative has developed a new generation of immunotherapy that has been reversed engineered from a human anti-tumor immune mechanism already known to be clinically effective. Research physicians have stated that the most powerful anti-tumor immune effect ever discovered for human cancer is the immune effect that occurs after a low intensity bone marrow/stem cell transplant with cells from a matched tissue donor ("Mini-Transplant"). This immune effect is called the graft vs. tumor ("GVT") effect. The GVT effect has been shown in numerous clinical studies to be capable of killing cancers that are refractory to standard treatments. However, the clinical application of this powerful GVT effect is limited by the severe and often lethal side effect of the Mini-Transplant procedure called graft vs. host disease ("GVHD"), where the transplanted cells attack and kill normal tissues of the host.

Immunovative has developed a patented cell product candidate called AlloStim(TM) that is designed to elicit the same GVT anti-tumor mechanism as occurs in the Mini-Transplant procedure without the GVHD toxicity. AlloStim(TM) also is designed to mediate these effects without the need for chemotherapy pre-conditioning or a matched tissue donor, as is required for the Mini-Transplant protocol. Immunovative has published the pre-clinical proof-of-concept data supporting this novel mechanism of action and has human clinical data available from an FDA-cleared Phase I/II clinical trial. The clinical data is currently being prepared for submission to a peer reviewed scientific journal.

AlloVax(TM) is an individualized cancer vaccine based upon the use of proteins called "chaperone proteins" or "heat shock proteins" that are purified from a sample of a patient's tumor. These chaperone proteins are known to carry tumor antigens, which are necessary for the immune system to identify the tumor and develop a lethal response to the tumor cells wherever they reside in the body. In published pre-clinical studies, scientists at the University of Arizona demonstrated that the combination of these chaperone proteins with AlloStim(TM) had a stronger anti-tumor effect than either one alone. In addition, it was shown that the combination had a novel mechanism of action, capable of shutting down the ability of the body's immune system to suppress immune attack on the tumor cells. AlloVax(TM) is designed to be used after surgical resection of a primary tumor to prevent tumor recurrence, but may also be used in advanced disease settings where no standard treatment options are available.

Dr. Michael Har-Noy, Founder and Chief Executive Officer of Immunovative, stated: "Harnessing the power of the immune system holds one of the greatest potentials for winning the battle against cancer. Immunotherapy with living immune cells is an emerging modality for cancer treatment that holds promise to provide cancer patients with anti-tumor benefits without the side-effects of current therapies. This class of therapy has the potential to work together with or replace current treatment methods. We have spent the last six months working closely with Novo on consummating this License Agreement. Our team looks forward to a long term, mutually beneficial relationship with Novo and its shareholders. We now plan to combine our skills so we can continue the clinical testing and advancement of our lead product candidates, AlloStim(TM) and AlloVax(TM), toward the goal of marketing approval."

"Licensing this important asset is consistent with Novo's strategy to transform the Company into a leader in the cancer therapy area," stated Antonio Treminio, President and Chief Executive Officer of Novo. "We are encouraged to have secured a high-quality, late-stage asset from a world-class partner. Immunovative's Product Candidates have significant potential not only to be a financial success, but also to make a significant difference in the lives' of cancer patients with unmet medical needs. We look forward to collaborating with Immunovative to advance the technology and assist in bringing these important Product Candidates to the market."

You can find a more in-depth summary of the License Agreement in our Current Report filed on Form 8-K today with the U.S. Securities and Exchange Commission as well as a full copy of the License Agreement attached thereto. The License Agreement and potential merger is a result of the renegotiation of the Memorandum of Understanding between Novo and Immunovative by which Novo agreed to acquire a subsidiary of Immunovative as announced on May 19, 2011. On September 29, 2011, Immunovative informed Novo that it received a letter from the U.S. Department of Health & Human Services, Food & Drug Administration (the "FDA"), dated September 26, 2011, in which the FDA proposed to terminate the Investigational New Drug Application ("IND") related to AlloStim(TM). On October 3, 2011, Novo voluntarily retracted the May 19, 2011 press release.

On November 14, 2011, Immunovative held a meeting with the FDA at their offices in Bethesda, Maryland. At that meeting, Immunovative presented the FDA with an oral and written point-by-point response to all the issues raised by the FDA in the letter of September 26, including 3 volumes of supporting documents. Immunovative subsequently filed reports containing the results of validation studies that were conducted and aimed at resolving the remaining outstanding issue that resulted in a clinical hold. Immunovative intends to continue to cooperate and work with the FDA to try to understand and resolve any remaining issues. The FDA is now studying the information submitted by Immunovative and has not yet made a determination on the status of the IND.

About Immunovative Therapies, Ltd.: Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at: www.immunovative.co.il

About Novo Energies Corporation: Novo Energies Corporation is in the process of transforming into the cancer therapy area and intends to institute a name and symbol change to better reflect the new direction of the Company. The name and symbol change are not conditions to the License Agreement.

DISCLAIMER

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on Novo's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Novo has little or no control. Such forward-looking statements are made only as of the date of this release, and Novo assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in Novo's Form 10-K for its fiscal year ended March 31, 2011, and other documents filed from time to time by Novo with the Securities and Exchange Commission.

For more information, please contact:

Mr. Antonio Treminio
Chairman & Chief Executive Officer
Novo Energies Corporation
New York: [phone]
Montreal: [phone]
Email: Email Contact

Dr. Michael Har-Noy
Founder & Chief Executive Officer
Immunovative Therapies, Ltd.
Israel Tel: [phone]
US Tel: [phone]
Email: Email Contact



SOURCE: Novo Energies Corporation

http://www.marketwatch.com/story/novo-energies-corporation-l…

[Gluecksjaeger]

Form 8-K for NOVO ENERGIES CORP


--------------------------------------------------------------------------------

15-Dec-2011

Entry into a Material Definitive Agreement, Termination of a Material Definiti

Item 1.01 Entry into a Material Definitive Agreement
On December 12, 2011, Novo Energies Corporation (the "Company") entered into a License Agreement (the "License Agreement") with Immunovative Therapies, Ltd., an Israeli Corporation ("Immunovative"), pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all product candidates (the "Licensed Products") based on Immunovative's current and future patents and a patent in-licensed from the University of Arizona. The license granted covers two experimental products for the treatment of cancer in clinical development called AlloStimTM and AlloVaxTM ("Licensed Products").

In exchange for the license, the Company has undertaken an obligation to pay Immunovative $10 million from the date of the License Agreement until the date that is two years after receiving notice from a regulatory agency in the US, Canada, EU or Thailand of approval to commence a Phase II/III clinical trial ("Regulatory Notice"). The $10 million due from the Company under the License Agreement is to be paid in the following installments: (i) $450,000 upon the signing of the Agreement, (ii) $150,000 at the start of each month after Immunovative submits to a peer-reviewed journal a manuscript for publication describing the results of the Phase I/II clinical trial conducted pursuant to IND 13,936l until the $10 million has been paid, (iii) $2 million within 60 days of receiving Regulatory Notice and (iv) at any time that the Company chooses prior to the dates above.

Upon successful completion of a randomized Phase II/III clinical trial (the "Clinical Trial") designed to prove the efficacy of at least one of the Licensed Products, the Company and Immunovative have agreed to consummate a merger transaction (either directly or through a subsidiary of the Company) with the Immunovative shareholders immediately prior to the merger owning 75% of the post-merger shares and the shareholders of the Company immediately prior to the merger owning 25% of the post-merger shares on a fully diluted basis. The successful completion of the Clinical Trial shall be defined as the date that the treatment protocol for the number of evaluable subjects necessary to conduct a statistical analysis comparing a placebo control group with a Licensed Product is completed, whereby there is sufficient power to detect a statistically significant (p<0.10) increase in overall survival of 50% or greater of the Licensed Product as compared to the placebo.

The License Agreement provides that the percentage of the post-merger shares that the shareholders of the Company immediately prior to the merger will obtain will increase in certain circumstances, including if the Company provides Immunovative more than the $10 million set out in the License Agreement and if Immunovative has outstanding debt (excluding any liabilities owed to patent attorney or for patent maintenance fees) at the time of the merger. Likewise the License Agreement provides that the percentage of the post-merger shares that the shareholders of the Company immediately prior to the merger will obtain will decrease in certain circumstances, including if Immunovative raises funds on its own or if the Company has outstanding debts at the time of the merger.

If there is a successful completion of a Clinical Trial but the Company has not paid the full $10 million, the parties may agree to merge or the Company may receive shares of Immunovative based on the amount of funds that the Company has provided Immunovative and the license will terminate. If there is not a successful completion of a Clinical Trial and the Company decides to continue to fund the clinical trials, the Company will receive shares in Immunovative for any additional payments more than $10 million. In each of these instances, the shares that Company will receive will be based on a valuation (prior to the funds provided by the Company) of Immunovative of $30 million, which can be decreased for any outstanding debts (with the exception of patent related debts and trade liabilities) of Immunovative or increased for any funds raised by Immunovative on its own.

If the Company pays all amounts due under the License Agreement, but there is no successful completion of a Clinical Trial, the Company and Immunovative may nevertheless agree to merge. If they do not, the Company shall maintain the license granted under the License Agreement.

Item 1.02 Termination of a Material Definitive Agreement
On May 17, 2011, the Company entered into a memorandum of understanding (the "MOU") with Immunovative's subsidiary, Immunovative Clinical Research, Inc. ("ICRI"), a Nevada Corporation, pursuant to which the Company and ICRI were to pursue a merger resulting in the Company owning ICRI. With the entry into the License Agreement, the Company and ICRI have terminated the MOU.

--------------------------------------------------------------------------------

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under
an Off-Balance Sheet Arrangement of a Registrant
If the Company created a Direct Financial Obligation by entering into the License Agreement, the terms of that Direct Financial Obligation are disclosed in Item 1.01 of this Current Report on Form 8-K.

Item 5.06 Change in Shell Company Status
Prior to the entry into the License Agreement, the Company was involved in the business of exploiting new technologies for the clean production of energy. The Company had invested significant time and resources into licensing technology to recycle tires and plastics into energy through a multi-stage hybrid gasification system. Upon entry into the License Agreement, the Company abandoned its prior business and has adopted the business of licensing new technologies aimed at harnessing the power of the immune system to treat cancer. Apart from the change in its business, most of the descriptions of the Company's other material information, including its management, capitalization, historical financial information and market information, contained in its annual report on Form 10-K for the year ended March, 31, 2011 and the quarterly reports filed on Form 10-Q for the quarters ended June 30, 2011 and September 30, 2011, are unaffected by the License Agreement and the change in its shell status. The Company hereby incorporates that annual report and those quarterly reports by reference. You may find copies of such reports filed with the US Securities and Exchange Commission on its website, www.sec.gov.

Item 8.01 Other Events
On December 15, 2011, the Company issued a press release entitled "Novo Energies Corporation Licenses Immunovative Therapies, Ltd.'s New Generation of Immunotherapy". A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.
Exhibits.

10.1 License Agreement, dated December 12, 2011
99.1 Press release entitled "Novo Energies Corporation Licenses Immunovative Therapies, Ltd.'s New Generation of Immunotherapy"

Quelle:http://biz.yahoo.com/e/111215/nvnc.ob8-k.html

[Gluecksjaeger]

Gestern +18,2% auf 0,13$, wenn auch bei relativ geringem Umsatz. Aber die Richtung stimmt schon mal.

[Gluecksjaeger]

+10% auf jetzt 0,154 US$ bei steigenden Umsätzen - und keiner merkt's. Mir soll's recht sein.

[Gluecksjaeger]

SK von gestern: 0,169 USD, + 20,7%

[Gluecksjaeger]

Heute schon wieder + 0,08 USD auf jetzt 0,26 USD = +46,86% bei über 4 Mio. Stck. Umsatz.

Wurde zwischenzeitlich übrigens in Immunovative umbenannt. WKN:

A1JX7M ISIN: US45255V1089

Performance seit meiner Erstempfehlung rd. + 130%.

Die Aktie scheint hierzulande aber keinen zu interessieren. Na ja, mir egal.